Active Ingredient(s): Niraparib
FDA Approved: * March 27, 2017
Pharm Company: * TESARO INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zejula Overview

Niraparib (originally MK-4827)[1] is an orally active[2] small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. On March 27, 2017 , the FDA approved it for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.[3] It is an inhibitor of PARP1 and PARP2.[4] Niraparib was granted fast track designation and Tesaro submitted a new drug app...

Read more Zejula Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Niraparib

Recent Zejula Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Niraparib or a similar ingredient: (1 result)